CRISPR Therapeutics vs Intellia Therapeutics
CRSP and NTLA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRSP and NTLA compare
CRISPR Therapeutics is the larger company, worth 2.8 times as much as Intellia Therapeutics ($3.9B against $1.4B).
Intellia Therapeutics grew revenue faster over the last twelve months (12.6% versus −64.8% for CRISPR Therapeutics).
Intellia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −672% compared with −3369% at CRISPR Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRSP | NTLA |
|---|---|---|
| Size and price | ||
| Market cap | $3.9B | $1.4B |
| Share price | $40.15 | $9.78 |
| Change, 1 year | −23.6% | 12.4% |
| Change, 5 years | −49.0% | −91.4% |
| Beta (5Y) | 1.59 | 1.65 |
| Employees | 393 | 377 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 290× | 23.0× (better) |
| P/B | 2.2× | 1.9× (better) |
| FCF yield | −9.6% (better) | −25.4% |
| Fair value | – | $9.13 |
| Margin of safety | – | −7.2% |
| Growth | ||
| Revenue growth (TTM) | −64.8% | 12.6% (better) |
| Revenue growth, 5Y average | 37.3% (better) | 3.1% |
| Profitability | ||
| Operating margin | −3990% | −712% (better) |
| Net margin | −3369% | −672% (better) |
| FCF margin | −2773% | −586% (better) |
| Return on equity | −26.1% (better) | −6425% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 17.85 (better) | 6.65 |
| Altman Z-score | 1.79 (better) | 0.86 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | −10.0% | – |
| Shareholder yield | −10.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 78.9% | 103% |
| Held by insiders | 2.7% | 2.0% |
| Insider net buying, 12 months | −$17.9M | −$869K (better) |
| Short interest, % of float | 18.3% | 32.3% |
Go deeper
- CRSP stock overview
- CRSP income statement
- CRSP valuation and score
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.